Search
for

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community fluridil (topilutamide) vs. cb-03-01 (clascoterone)

      in Research/Science  4 upvotes 2 years ago
      The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

      community cb-03-01 research chem (winlevi/clascoterone cream)

      in Technology  3 upvotes 2 years ago
      The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

      community Pyrludimide (KX-826) or Breezula (clascoterone)

      in Treatment  8 upvotes 5 days ago
      The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

      community Breezula - who tried CB0301/Clascoterone from gray marked/pharmas ?

      in Research/Science  1 upvotes 2 months ago
      The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.